Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol for Transient Tachypnea of the Newborn
NCT06921291Phase 1Completed
- Sponsor
- Khyber Teaching Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of salbutamol in transient tachypnea of the newborn (TTN) (2 arms), sponsored by Khyber Teaching Hospital. Primary endpoint: Mean change in Transient Tachypnea of the Newborn Score at 4 hours. Started Aug 2024; status: completed.
02
Drugs
salbutamol
03
Conditions
transient tachypnea of the newborn (TTN)
Beyond the preview
Go deeper on NCT06921291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921291.